Beat
Drug trials, gene editing, and longevity — the science with the caveats intact.
The FDA delays a rare-epilepsy drug three months — and analysts blame last year's staff cuts →
A finished drug application sits in a longer queue, as the agency that reviews it runs shorter on people. Plus a gene therapy chief steps down, and a busy week of new results piling up behind them.
The FDA seats a panel on wellness peptides — and most of the panelists sell them →
A US committee that will decide whether pharmacies can make seven unproven peptides is now stacked with people who prescribe and profit from them. Plus a mechanism for how Alzheimer's spreads, and two more late-stage trial flops.
A big fish-oil trial proves the pills reach the brain — and do nothing for it →
Americans spend over $1bn a year on omega-3 supplements for memory. A two-year USC trial confirmed the omega-3 got into the brain, then found no benefit to memory or to the brain shrinkage that tracks Alzheimer's. The same week showed the wider pattern: demand for peptides and weight-loss drugs is racing ahead of the proof.
An LSD pill posts the best depression data the field has seen — and the hardest result to read →
Definium's psychedelic drug beat placebo by 8.1 points in a phase 3 trial and sent its shares up 55%. The number is real; the trouble is that a drug which makes you trip can't be tested blind, so no one can fully separate the drug from the patient knowing they got it.
The week age stopped meaning your birthday — and a body clock predicted cancer →
A 154,000-person study found a generation's bodies are ageing faster than the calendar says, and that the gap predicts who gets cancer young. Plus a Yale study where half of older adults got better, not worse, and a family-tree hunt that narrowed the genes for a long healthy life from 20,000 to 12.
Soil bacteria carry a built-in four-drug antibiotic cocktail — and it's hard to outrun →
A single gene cluster in common soil bacteria makes four antibiotics at once, all hitting the same essential pathway in different places. Bacteria can dodge one drug; dodging four is far harder.
The company that invented gene editing went bankrupt the week the field had its biggest wins →
Sangamo Therapeutics, which coined the term "genome editing" 20 years ago, filed for Chapter 11 — the same week a CRISPR rival posted a landmark trial and a man was cured of sickle cell. The pioneer built the road; the followers are driving it.
A US company will sell an unproven anti-ageing gene therapy abroad to skip the FDA →
Minicircle is about to offer a longevity gene therapy in Honduras, the Bahamas and Panama with no rigorous trials and no regulator's approval — while the field that plays by the rules saw real cures, real failures, and a pioneer go bankrupt.
The week three big drug bets failed — and what the winners' headlines hide →
Pfizer, Exelixis and Novocure all saw late-stage trials fall short this week, even as the LSD pill and the $10.9bn deal grabbed the cheers. A normal week in biotech is mostly failure — we just rarely hear about it.
The week HIV funding shrank while $745m flowed into the drugs that pay →
As the US cut money for HIV research and care, hundreds of millions poured into commercially attractive biotech — a snapshot of how funding, not need, decides which science advances.
AbbVie bets nearly $11bn on a biotech whose drugs aren't proven yet — and it wasn't alone this week →
A wave of pharma dealmaking, led by AbbVie's roughly $11 billion move for Apogee Therapeutics, shows big drugmakers buying promising science years before it's certain to work.
A one-time gene edit cut a rare disease's attacks by 87% — the first phase 3 proof that CRISPR works inside the body →
Intellia's in-vivo CRISPR treatment for hereditary angioedema posted the first late-stage results for editing genes inside a living person. Plus the FDA's softer line on rare-disease gene therapy, a new antifungal as resistance climbs, and an $11bn deal.
An mRNA flu shot goes to the FDA — and the math of giving anything to millions →
A US advisory panel weighed Moderna's mRNA flu vaccine this week. The bigger story is what happens to rare risks and tiny benefits once a shot reaches tens of millions of arms.
The week the FDA changed its mind about what counts as proof →
A gene therapy for Huntington's got a green light it was denied three months ago, on the same data — a reminder that the evidence bar for approval is a judgment call, not a fixed line, and the line moved this week.
The week a 200,000-woman cancer screening trial finally explained why it failed →
A near-perfect ovarian cancer test still saved no lives — a lesson in why a rare disease defeats even an accurate screen. Plus a prenatal blood test reads 23,000 genes, an AI flags a clot a doctor missed, and HPV shots push cervical-cancer death toward zero.
A depression drug just lost to a sugar pill three times in a row →
Neumora's navacaprant failed its third and final late-stage depression trial — in one study, patients on the placebo did better. The week's other results show what beating a sugar pill actually looks like.
Scientists edited the red out of lettuce — and other compounds quietly took its place →
A gene edit switched off red lettuce's pigment, but the molecules it was made from didn't vanish. They piled up and poured into a different compound instead, with the plant growing normally — a vivid reminder that you can't subtract one thing from a living system, only redirect it.
The week a therapy to make old cells young again was put into a person for the first time →
Life Biosciences dosed the first patient in a trial that switches on three genes to partially rewind ageing cells — starting, carefully, in the eye. Plus off-the-shelf CAR-T matches the bespoke kind, a $10.6bn cancer buyout, and a drug to stop immunotherapy's deadliest side effect.
The week the weight-loss drugs admitted what "weight" leaves out →
A new trial, a wearable study, and a string of conference data all circled the same blind spot in the obesity-jab boom — the scale can't tell muscle from fat, and a third of the loss is the wrong kind.
A cancer therapy just put five lupus patients into remission — and it points at a dozen more diseases →
A one-time treatment built to kill blood cancer reset the immune systems of patients with severe lupus. The same tool is now being aimed at MS and rheumatoid arthritis.
The week antibiotic resistance got the AI treatment — and a warning that even the leftovers train the bugs →
Researchers turned a suite of AI tools loose on the search for new antibiotics, while a separate study found that the breakdown products of old ones drive resistance nearly as hard as the drugs themselves. Plus a world-first cell-rejuvenation trial, a 1920s vaccine helping diabetes, and a drug to save muscle on weight-loss jabs.
Scientists precisely edited human embryos for the first time — and the edit didn't stay put →
A US-led team used base editing to correct disease mutations in human embryos with a precision standard CRISPR can't match. The same week showed how far the tool still is from a baby — and how fast the rest of the field is moving.
Ebola is winning in Congo — not because the science failed, but because the system around it did →
One of the largest Ebola outbreaks ever is outrunning the response in eastern Congo, where medics improvise without boots or masks while donors scramble. The week's other science news was full of vaccines being built. The gap between the two is the whole story.
A startup with no human data just raised $435 million to reverse ageing →
This week the biggest numbers in biotech went to the least proven ideas — a longevity company about to run its first-ever human trial pulled in $435M, while a company with an actual drug got stopped cold by the FDA. The gap between the two is the whole story.
The week's biggest medical news wasn't a drug — it was who's allowed to sell one →
A unanimous Supreme Court ruling on generic drugs, and a fight over who gets to jump the FDA's queue, decided more about which medicines you can actually afford than any lab result did. The molecule is the easy half; the rules are the other half.
A cancer drug that pulls off tumours' invisibility cloak — and the week the caveats mattered →
At the world's biggest cancer meeting, an Oxford drug shrank tumours in patients who had run out of options. The same week showed why one good result is never the whole story.
An AI-designed vaccine clears its first human trial →
For the first time, a vaccine whose key component was designed by AI passed a first-in-human test — a real milestone, with real caveats — while big money bets on AI-designed drugs, an Ebola outbreak outruns the science, and longevity raises hundreds of millions before its first trial.
The new cancer drugs don't fight harder — they strip the disguise →
At the world's largest cancer meeting, the standout results came from treatments that unmask tumours so the immune system can find them. Plus: weight-loss drugs keep showing benefits far beyond weight, gene therapy gets a regulatory tailwind, and an honest answer on how long humans can live — we don't know.
Cancer survives by hiding — and this week's news is about making it visible again →
At the big annual cancer meeting, the theme was the same trick from many angles: tumours stay alive by hiding from the immune system, so the new treatments strip the disguise or train the body to see through it. One study found the hiding itself can be a weakness. Plus a longevity startup raises $435 million before its first human trial, a masterclass in reading past a trial headline, and a lawsuit about why consent exists.
The weight-loss drugs keep doing things they weren't designed to do →
Two large studies this week tie GLP-1 drugs to less cancer and less addiction — both are association, not proof. Plus real cancer-immunotherapy wins, a hepatitis B near-cure, and a longevity reality check.